H.B. Fuller rejected Ancora's second offer for its Building Adhesive Solutions segment, citing undervaluation. Retaining BAS supports funding for medical asset integration and a strategic shift to hig
H.B. Fuller shares fell 25.4% over three years following an $850 million debt issuance, though a DCF model suggests the stock remains 26% undervalued despite integration risks.
H.B. Fuller prices $850 million in senior unsecured notes to finance the acquisition of Advanced Medical Solutions Group plc. This strategic move aims to expand the company's specialty chemicals exper
H.B. Fuller reported a 5.2% revenue increase and 21% EPS surge for Q3, raising guidance with $75 million in planned annualized cost savings by 2030. However, declining demand and acquisition leverage
H.B. Fuller Company reported Q3 revenue of $938.2 million, falling short of FactSet estimates. The company also announced the cancellation of Ancora Holdings Group's acquisition of its Building Adhesi
H.B. Fuller posted strong Q3 2026 results with $938 million in revenue and 21% EPS growth, achieving a record 19.9% EBITDA margin. The company updated its fiscal outlook and highlighted the strategic
H.B. Fuller forecasts Q3 EPS of $1.47, a 15.9% increase, with revenue growing 5.4% to $945.59 million. Despite rejecting an acquisition, Citigroup remains bullish ahead of the September 23 earnings re
H.B. Fuller is reviewing an unsolicited $1.1 billion to $1.2 billion offer from Ancora Holdings to acquire its Building Adhesive Solutions segment. The move aims to improve the company's cost base and
Analysts rate H.B. Fuller (FUL) as a "Buy," projecting next quarter revenue of $948.19M and EPS of $1.47 amid peer comparisons in the Chemicals industry.
Zacks' ranking system identifies H. B. Fuller (FUL) as an undervalued opportunity with a Buy rank and favorable valuation metrics compared to industry averages.
Fluor Corporation prepares Q1 earnings release with analysts anticipating profit growth despite revenue dips. Key focus lies on whether LNG, mining, and nuclear project pipelines can sustain profitabi
H.B. Fuller reported stronger Q2 and six-month fiscal 2026 results alongside completing an $89.49 million share repurchase program. While earnings resilience is highlighted, investors remain mindful o
H.B. Fuller reported solid Q2 earnings with record cash flow despite raw material inflation and supply chain challenges. The company updated full-year guidance while noting investor concerns over leve
H.B. Fuller reported improved Q2 2026 results with higher revenue and margins, challenging bearish leverage narratives despite debt concerns. Operational efficiency gains were highlighted, though inve
H. B. Fuller released its fiscal Q2 earnings snapshot. While the quarterly report was confirmed, specific financial details were not included in this brief update.
H.B. Fuller Company reported Q2 revenue of $950.3 million, exceeding FactSet estimates of $924.8 million. The company also raised its fiscal 2026 adjusted EPS guidance to a range of $4.60-$4.90.
H.B. Fuller Company (FUL) is scheduled to release its earnings report, highlighting its strong position in the adhesives and sealants market with a GF Score of 80/100. Investors are monitoring the eve
H.B. Fuller will report Q2 fiscal 2026 results on June 25, with projected EPS of $1.38 and 3.0% revenue growth. Analysts expect margin expansion driven by operational efficiency and raw material cost
H.B. Fuller will report Q2 2024 earnings post-market on June 24, with analysts forecasting $1.09 EPS and $907.7 million revenue.
H.B. Fuller prepares for Q2 earnings on June 24 with projected EPS of $1.38 and revenue of $923.62 million. Analysts have updated ratings following a 4.3% dividend hike.
H.B. Fuller released its 2025 Sustainability Report detailing 2030 emission and waste goals, coinciding with significant stock momentum. Analysts indicate the stock may be 8% undervalued relative to a
H.B. Fuller is set to release Q2 2026 earnings on June 24th, with analysts expecting $1.37 per share. The company recently increased its quarterly dividend to $0.245 per share prior to the scheduled c
H.B. Fuller faces uncertain future outlook due to activist pressure opposing its pursuit of Advanced Medical Solutions Group. Analysts maintain a stable fair value around $70 despite mixed views on ex
Kennedy Capital Management LLC increased its stake in specialty chemicals firm H.B. Fuller by 43.4% in Q4, holding shares worth $37.5 million. The move follows stronger-than-expected earnings and a di
H.B. Fuller Company will release its second quarter fiscal 2026 financial results after market close on June 24, 2026. An investor conference call will follow on June 25, 2026, to discuss the findings
Activist investor Ancora Holdings urged H.B. Fuller to abandon its acquisition of Advanced Medical Solutions Group, citing leverage concerns. Consequently, H.B. Fuller's stock fell 5.1% as investors s
Activist investor Ancora Holdings Group urges H.B. Fuller to halt its acquisition of Advanced Medical Solutions Group citing leverage and integration risks. This opposition highlights a strategic dive
JPMorgan upgraded H.B. Fuller to Neutral with a $58 price target amid activist pressure to review its acquisition of Advanced Medical Solutions. The company manufactures adhesives, sealants, and speci
Penn Capital Management reduced its stake in H.B. Fuller by 16% in Q4, selling 23,894 shares. While EPS beat estimates, revenue fell short at $770.84 million.
JPMorgan upgraded HB Fuller to Neutral from Underweight with a $58 price target, citing strategic uncertainty. While the company maintains a strong dividend record, analysts warn of difficulties for l
H.B. Fuller shares trade below narrative fair value at $59.95, suggesting potential undervaluation despite elevated P/E ratios. The company targets over 20% EBITDA margins through cost streamlining wh
Financial analysis evaluates H.B. Fuller's valuation following a share price drop, with DCF and P/E metrics offering mixed signals on overvaluation relative to industry standards.
Eastman Chemical reported a 5% Q1 2026 revenue decline but projects a strong Q2 rebound driven by volume growth and margin improvements in its Chemical Intermediates segment amidst geopolitical disrup
Vanguard Portfolio Management disclosed a 6.91% beneficial ownership stake in H.B. Fuller Co (FUL) totaling 3.77 million shares as of March 31, 2026, via a Schedule 13G filing.
Boliden reported Q1 earnings beating estimates despite seismic disruptions at its Garpenberg zinc mine, lowering volume guidance to 1.5 million tonnes. Operations are set to resume in Q2 at a reduced
Analyst projections indicate H.B. Fuller expects year-over-year revenue growth in Q2, though EPS may slightly decline. The analysis reviews key metrics and factors influencing current market expectati
HB Fuller prepares to announce Q1 2026 earnings, with market analysts previewing financial performance metrics prior to the official release.
Dow Inc. reported Q1 earnings beating estimates, driven by sales surges from Middle East supply chain disruptions. Management expects pricing gains and market dynamics to support performance through 2
Baird Securities has maintained its Buy rating on H.B. Fuller (FUL.US), providing no specific rationale or financial analysis in the update.
The Mosaic Company (MOS) is flagged as the most oversold materials stock via RSI analysis ahead of Q1 earnings. The report lists top 10 undervalued opportunities in the materials sector for investors.
H.B. Fuller increased its quarterly dividend to $0.2450 per share, maintaining a 58-year streak despite raw material inflation. The decision follows positive Q1 2026 earnings and higher revenue guidan
H. B. Fuller updated its FY 2026 earnings guidance to $4.55–$4.90 per share, aligning with consensus estimates. Shares rose 2.2% following the announcement, while CEO Celeste Beeks Mastin significantl
H.B. Fuller is set to release its Q1 earnings report, expected to highlight key financial metrics such as revenue and earnings per share. This analysis aims to provide insights into the company's rece
H.B. Fuller reported strong first-quarter results and raised its full-year 2026 revenue guidance, though analysts remain split on its valuation between $57.26 and $70.71. Investors weigh potential mar
ChemBrief